Our Portfolio

Expanded Access Policy

SparingVision is a clinical-stage genomic medicine company developing gene therapies designed to preserve and restore vision in patients with degenerative retinal diseases.

Clinical trials are essential to evaluating the safety and effectiveness of investigational gene therapies and are the primary way patients may access these therapies prior to regulatory approval.

While expanded access (also known as early access programs) may be available in limited circumstances, SparingVision does not currently provide expanded access to any of its investigational gene therapies, given the early stage of our development programs.

Information about our ongoing clinical trials can be found at https://clinicaltrials.gov/.

For questions about this policy or about SparingVision, please contact info@sparingvision.com.

As development programs evolve and additional data become available, SparingVision may reevaluate this policy, in accordance with applicable laws and regulations.